Association of urinary polycyclic aromatic hydrocarbons and serum C-reactive protein.

[1]  P. Libby.  Inflammation in Atherosclerosis , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[2]  P. Ridker.  C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. , 2009, Clinical chemistry.

[3]  S. Caudill,et al.  Concentration and profile of 22 urinary polycyclic aromatic hydrocarbon metabolites in the US population. , 2008, Environmental research.

[4]  G. Hansson,et al.  Introduction: Atherosclerosis as inflammation: a controversial concept becomes accepted , 2008, Journal of internal medicine.

[5]  D. Grönemeyer,et al.  Sex related cardiovascular risk stratification based on quantification of atherosclerosis and inflammation. , 2008, Atherosclerosis.

[6]  A. Mainous,et al.  Effect of Psyllium Fiber Supplementation on C-Reactive Protein: The Trial to Reduce Inflammatory Markers (TRIM) , 2008, The Annals of Family Medicine.

[7]  P. Ridker.  C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. , 2007, Journal of the American College of Cardiology.

[8]  J. Mega,et al.  Cholesterol, C-reactive protein, and cerebrovascular events following intensive and moderate statin therapy , 2006, Journal of Thrombosis and Thrombolysis.

[9]  Zheng Li,et al.  Measurement of urinary monohydroxy polycyclic aromatic hydrocarbons using automated liquid-liquid extraction and gas chromatography/isotope dilution high-resolution mass spectrometry. , 2006, Analytical chemistry.

[10]  Nancy R Cook,et al.  The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women , 2006, Annals of Internal Medicine.

[11]  Lovisa C. Romanoff,et al.  Automated solid-phase extraction method for measuring urinary polycyclic aromatic hydrocarbon metabolites in human biomonitoring using isotope-dilution gas chromatography high-resolution mass spectrometry. , 2006, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[12]  A. Mainous,et al.  Combining serum biomarkers: the association of C-reactive protein, insulin sensitivity, and homocysteine with cardiovascular disease history in the general US population , 2006, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

[13]  S. Caudill,et al.  Reference range levels of polycyclic aromatic hydrocarbons in the US population by measurement of urinary monohydroxy metabolites. , 2006, Environmental research.

[14]  A. Mainous,et al.  Fiber and C-reactive protein in diabetes, hypertension, and obesity. , 2005, Diabetes care.

[15]  O. Wagner,et al.  Inflammation and Carotid Artery—Risk for Atherosclerosis Study (ICARAS) , 2005, Circulation.

[16]  D. Hood,et al.  Bioavailability and Risk Assessment of Orally Ingested Polycyclic Aromatic Hydrocarbons , 2004, International journal of toxicology.

[17]  Reinhard Niessner,et al.  Polycyclic aromatic hydrocarbons in urban air particulate matter: decadal and seasonal trends, chemical degradation, and sampling artifacts. , 2003, Environmental science & technology.

[18]  Sidney C. Smith,et al.  MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION , 2003 .

[19]  K. Yano,et al.  C-Reactive Protein and the Future Risk of Thromboembolic Stroke in Healthy Men , 2003, Circulation.

[20]  Yu-ling,et al.  Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. , 2003, Circulation.

[21]  Nancy R Cook,et al.  Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. , 2002, The New England journal of medicine.

[22]  Robert Detrano,et al.  Combined Use of Computed Tomography Coronary Calcium Scores and C-Reactive Protein Levels in Predicting Cardiovascular Events in Nondiabetic Individuals , 2002, Circulation.

[23]  A. Seidel,et al.  Biomonitoring of polycyclic aromatic hydrocarbons in human urine. , 2002, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[24]  A. Peters,et al.  Particulate air pollution is associated with an acute phase response in men; results from the MONICA-Augsburg Study. , 2001, European heart journal.

[25]  J. Danesh,et al.  Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses , 2000, BMJ : British Medical Journal.

[26]  G. Scherer,et al.  Biomonitoring of exposure to polycyclic aromatic hydrocarbons of nonoccupationally exposed persons. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[27]  R J Glynn,et al.  C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.

[28]  P. Ridker,et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.

[29]  M. Pepys,et al.  Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease. , 1993, The Journal of clinical investigation.

[30]  G. Moneta,et al.  Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein , 2009 .

[31]  Hisashi Adachi,et al.  Inflammation, atherosclerosis, and coronary artery disease. , 2005, The New England journal of medicine.